Cambridge, MA
Bicara Therapeutics, a wholly-owned subsidiary of Biocon based in Boston, U.S., is developing a pipeline of bifunctional antibodies that exploit the recent advances in immuno-oncology. Bicara enables access to the thriving innovation ecosystem in the U.S. which accelerates the development of cutting-edge therapies for cancer. Synergies between the scientific teams in Boston and Bengaluru will pioneer rapid and cost-effective breakthrough innovation.
bicara.comThese are collections Bicara Therapeutics is a part of. Click on the collection name to view similar companies.
IPO
Unknown
Series C
$165,000,000
Series B
$108,000,000
Seed
$40,000,000
0 out of 5 stars
Based on 0 reviews
Worked here? Share your experience. Help others decide if this company is right for them. Write a review on Bicara Therapeutics.